Avoid common mistakes on your manuscript.
Correction to: Diabetes Ther https://doi.org/10.1007/s13300-019-0630-6
In the original publication, Figs. 3 and 5 and the final sentence in the final paragraph of Results/Sensitivity Analyses were incorrectly published. The corrected statement and the figures are given below.
Additionally, the last few lines under the heading ‘Sensitivity Analyses’ should read as:
At a willingness-to-pay threshold of DKK 250,000 per QALY gained (a representative value based on GBP 20,000 in the UK), the probabilities of once-weekly semaglutide 0.5 mg and 1 mg being considered cost-effective were 72.4% and 96.5%, respectively, versus dulaglutide 1.5 mg (Fig. 5).
Discounted direct costs over patient lifetimes in the primary analysis based on SUSTAIN 7. DKK 2017 Danish kroner
Cost-effectiveness acceptability curve for the primary analysis versus dulaglutide, based on SUSTAIN 7. DKK 2017 Danish kroner, QALY quality-adjusted life year
Open Access
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Gæde, P., Johansen, P., Tikkanen, C.K. et al. Correction to: Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting. Diabetes Ther 10, 1319–1321 (2019). https://doi.org/10.1007/s13300-019-0638-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13300-019-0638-y